Homoharringtonine and omacetaxine for myeloid hematological malignancies

@inproceedings{L2014HomoharringtonineAO,
  title={Homoharringtonine and omacetaxine for myeloid hematological malignancies},
  author={Shuqing L{\"u} and Jianmin Wang},
  booktitle={Journal of hematology & oncology},
  year={2014}
}
Homoharringtonine (HHT), a plant alkaloid with antitumor properties originally identified nearly 40 years ago, has a unique mechanism of action by preventing the initial elongation step of protein synthesis. HHT has been used widely in China for the treatment of chronic myeloid leukemia (CML), acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Omacetaxine, a semisynthetic form of HHT, with excellent bioavailability by the subcutaneous route, has recently been approved by FDA of… CONTINUE READING
Highly Cited
This paper has 44 citations. REVIEW CITATIONS
17 Extracted Citations
96 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 17 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 96 references

YZ: 106 cases of acute myeloid leukemia treated with HA or DA regimen

  • YH Fu, Liu
  • 2001
Highly Influential
15 Excerpts

The clinic study of therapy in the chronic myelocytic leukemia-chronic phase by AS2O3 combined with homoharringtonine

  • ZG He, LJ Hou, JB Xu
  • J Med Res
  • 2008
Highly Influential
11 Excerpts

The treatment of harringtonine in 13 patients with myelodysplastic syndrome

  • PS Cao, X Liu
  • Chin J Hematol
  • 1990
Highly Influential
15 Excerpts

ZP: The treatment of HA regimen in 34 patients with acute non-lymphocytic leukemia

  • BG Zheng, XS Luo, +4 authors Hu
  • Chin J Hematol
  • 1989
Highly Influential
14 Excerpts

Similar Papers

Loading similar papers…